Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Positive DOORwaY90 Liver Cancer Trial Results

Grand Pharmaceutical Group (SEHK:512) just reported that its DOORwaY90 trial for SIR-Spheres Y-90 in unresectable hepatocellular carcinoma met its clinical endpoint, a key data point for investors watching its radiopharmaceutical pipeline. See our latest analysis for Grand Pharmaceutical Group. The DOORwaY90 success comes at a time when Grand Pharmaceutical Group’s short-term share price performance has been weak, with a 30-day share price return showing a decline of 5.35% and a 90-day share price return showing a decline of 16.69%. However, its 1-year and 3-year total shareholder returns of 11.04% and 54.32% respectively highlight longer-term momentum that has rewarded patient holders. If this kind of clinical progress catches your eye, it could be a moment to see what else is setting the pace in healthcare-focused names, starting with 127 healthcare AI stocks With Grand Pharmaceutical Group trading at HK$6.54 and at a 24% intrinsic discount with a value score of 5, as well as a sizeable gap to analyst targets, is there still a buying opportunity here or has the market already priced in future growth? Price to earnings of 18.5x: Is it justified? Grand Pharmaceutical Group trades on a P/E of 18.5x, which screens as good value versus its peer average of 29.6x while still sitting above the Hong Kong pharmaceuticals industry average of 15x. The P/E ratio compares the current share price with earnings per share, so it effectively reflects how much investors are willing to pay for each dollar of profit. For a business with HK$12,283.27m in revenue and HK$1,240.87m in net income, this is a common yardstick investors use to judge whether the HK$6.54 share price aligns with current earnings power. Here, the market is pricing Grand Pharmaceutical Group below the peer average multiple, which can suggest expectations that are more restrained than for some competitors. At the same time, the current P/E sits above the estimated fair P/E of 22.5x that our model points to as a level the market could move towards if forecasts and cash flows play out as expected. Against the broader Hong Kong pharmaceuticals industry, the current 18.5x P/E is higher than the 15x industry average, which implies investors are already paying a premium versus many sector names. Compared with peers on 29.6x and an estimated fair P/E of 22.5x, the current valuation sits in the middle, suggesting the stock is not priced as aggressively as higher multiple names but is also not trading like a clear bargain within the sector. Explore the SWS fair ratio for Grand Pharmaceutical Group Result: Price-to-earnings of 18.5x (ABOUT RIGHT) However, you still need to weigh risks such as execution on its broad R&D partnerships, as well as the recent 30 to 90 day share price weakness. Find out about the key risks to this Grand Pharmaceutical Group narrative. Another view: What the DCF says On top of the 18.5x P/E, the SWS DCF model values Grand Pharmaceutical Group at HK$8.65 per share versus the current HK$6.54, which points to the shares trading at about a 24% discount. If that gap persists, consider how much weight you should really give the earnings multiple. Look into how the SWS DCF model arrives at its fair value. 512 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Grand Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 234 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mix of clinical progress and recent share price weakness can lead to differing opinions, so consider acting while the information is fresh and weigh the data for yourself using 3 key rewards and 1 important warning sign Looking for more investment ideas? If Grand Pharmaceutical Group has caught your attention, do not stop here. Broaden your watchlist with a few focused sets of stocks that match different goals. Target potential mispricings across the market by reviewing 234 high quality undervalued stocks and see which companies currently look cheap relative to their fundamentals. Strengthen your search for resilience by scanning the solid balance sheet and fundamentals stocks screener (385 results) and focus on businesses with financial footing that may better withstand shocks. Spot opportunities before the crowd by checking the screener containing 567 high quality undiscovered gems and find quality names that are not yet widely followed. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free